To determine the effect of baseline estimated glomerular filtration rate (eGFR) on the causal association between intravenous iodinated contrast material exposure and subsequent development of acute kidney injury (AKI) in propensity score-matched groups of patients who underwent contrast material-enhanced or unenhanced computed tomography (CT).
Purpose:
To determine the effect of baseline estimated glomerular filtration rate (eGFR) on the causal association between intravenous iodinated contrast material exposure and subsequent development of acute kidney injury (AKI) in propensity score-matched groups of patients who underwent contrast material-enhanced or unenhanced computed tomography (CT).
Materials and Methods:
This retrospective study was HIPAA compliant and institutional review board approved. All patients who underwent contrast-enhanced (contrast material group) or unenhanced (non-contrast material group) CT between 2000 and 2010 were identified and stratified according to baseline eGFR by using Kidney Disease Outcomes Quality Initiative cutoffs for chronic kidney disease into subgroups with eGFR of 90 or greater, 60-89, 30-59, and less than 30 mL/min/1.73 m 2 . Propensity score generation and 1:1 matching of patients were performed in each eGFR subgroup. Incidence of AKI (serum creatinine [SCr] increase of 0.5 mg/dL [44.2 mmol/L] above baseline) was compared in the matched subgroups by using the Fisher exact test.
Results:
A total of 12 508 propensity score-matched patients with contrast-enhanced and unenhanced scans met all inclusion criteria. In this predominantly inpatient cohort, the incidence of AKI significantly increased with decreasing baseline eGFR (P , .0001). However, this incidence was not significantly different between contrast material and non-contrast material groups in any eGFR subgroup; for the subgroup with eGFR of 90 or greater (n = 1642), odds ratio (OR) was 0.91 (95% confidence interval [CI]: 0.38, 2.15), P = .82; for the subgroup with eGFR of 60-89 (n = 3870), OR was 1.03 (95% CI: 0.66, 1.60), P = .99; for the subgroup with eGFR of 30-59 (n = 5510), OR was 0.94 (95% CI: 0.76, 1.18), P = .65; and for the subgroup with eGFR of less than 30 mL/min/1.73 m 2 (n = 1486), OR was 0.97 (95% CI: 0.72, 1.30), P = .89.
Conclusion:
Diminished eGFR is associated with an increased risk of SCr-defined AKI following CT examinations. However, the risk of AKI is independent of contrast material exposure, even in patients with eGFR of less than 30 mL/min/1.73 m
Study Design
Study design and implementation for this retrospective study were overseen by the institutional review board of the Mayo Clinic (Rochester, Minn) and conformed to Health Insurance Portability and Accountability Act guidelines on patient data integrity. Clinical data were extracted from our institutional electronic medical record, as previously described (5) . Clinical diagnoses and procedures were identified from the electronic medical record by using International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) diagnostic codes and Current Procedural Terminology procedure codes. The SCr data were extracted from our institutional laboratory information system and were associated with the date and time of CT, as previously described (5).
Study Population
All patients in the current study were included in a previous study (5) in which retrospective and prospective studies. However, a recent meta-analysis of 13 retrospective controlled studies of intravenous contrast material administration demonstrated a similar likelihood of AKI between patients who received intravenous contrast material and patients who did not (4) . Further, a recent, large controlled retrospective study of patients who underwent computed tomography (CT) also demonstrated similar rates of AKI between propensity score-matched patients who underwent contrast material-enhanced CT and patients who underwent unenhanced CT (5). These findings suggest that the true incidence of CIN following intravenous contrast material exposure is much lower than what has been estimated (6) (7) (8) .
Equations to calculate the estimated glomerular filtration rate (GFR) (eGFR) from the serum creatinine (SCr) level demonstrate superior correlation with actual GFR, as compared with SCr measurements alone (9, 10) , and because of this finding, some authorities speculate that calculation of the eGFR may provide a better assessment of AKI risk prior to administration of potentially nephrotoxic agents (1, 2, 11, 12) . The purpose of the current study was to determine the effect of baseline eGFR on the causal association between intravenous iodinated contrast material exposure and subsequent development of AKI in propensity score-matched groups of patients who underwent contrast-enhanced or unenhanced CT.
Materials and Methods
Investigator-initiated grant support for this study was provided to two authors (J.S.M. and E.E.W.) by GE Healthcare (Princeton, NJ). No author of this study is a consultant to this company, and the I ntravenous contrast material exposure has long been held to be a common cause of acute kidney injury (AKI), otherwise known as contrast material-induced nephropathy (CIN). Concern in regard to the development of CIN has had a dramatic effect on clinical practice for decades (1) (2) (3) , where intravenous contrast material is commonly withheld among "highrisk" individuals, often at the expense of diagnostic accuracy. These concerns notwithstanding, the true incidence of contrast material-mediated AKI remains relatively undefined because of the scarcity of properly controlled Implication for Patient Care n Contrast material-induced nephropathy cannot be differentiated from contrast materialindependent causes of AKI, in a predominantly inpatient cohort, even in patients with severely compromised renal function. 
Advances in Knowledge

Statistical Analysis
All statistical analyses were performed by using R (version 2.15; R Foundation for Statistical Computing) (16) and JMP (version 9; SAS Institute, Cary, NC). Continuous data were displayed as median scores with IQRs because of nonnormal distributions and were compared by using the Wilcoxon signed-rank test. Categorical data were displayed as relative frequencies (percentages) and were compared by using x 2 tests of significance. The incidence of AKI was compared between contrast material and non-contrast material groups following propensity score matching by using the Fisher exact test. Significance was assigned to differences with P  .05.
Results
Study Population and Propensity Score Adjustment
Inclusion and exclusion criteria of this study population have been described previously (5) . Among 1 029 899 scan records examined between 2000 and 2010, 41 249 scan records from 41 249 patients met all inclusion criteria for propensity score matching. Propensity score distributions for each eGFR Accordingly, eGFR results prior to this date were calculated by using the original MDRD equation, and results after this date were calculated by using the revised, isotope dilution mass spectrometry-traceable MDRD equation. In cases where multiple SCr results existed in this 24-hour period, the average SCr level was used. Patients were stratified into subgroups according to baseline eGFR of 90 or higher, 60-89, 30-59, and lower than 30 mL/min/1.73 m 2 to mirror KDOQI guidelines to classify chronic kidney disease (11). An analysis of the subgroup with eGFR of lower than 15 mL/min/1.73 m 2 was not performed because of insufficient sample size (, 100 contrast-enhanced scans).
Clinical and Outcome Variables
Demographic variables (age, sex, race), pre-and postscanning SCr results, and predisposing comorbidities reportedly associated with development of AKI following contrast material administration (diabetes mellitus, diabetic nephropathy, chronic renal failure, acute renal failure, and congestive heart failure) were extracted from the electronic medical record, as previously described. A Charlson comorbidity score was calculated for each patient by using 160 ICD-9-CM codes for relevant comorbidities, as previously described (5) .
Postscanning AKI was defined as a maximum increase in SCr level of 0.5 mg/dL or greater (44.2 mmol/L) over baseline (mean SCr level 24 hours prior to scanning) in the 24-72 hours following CT. An SCr level-defined cutoff of AKI was chosen for this study because eGFR cutoffs have not yet been thoroughly validated or standardized in the setting of contrast material-mediated AKI.
Propensity Score Analysis
Propensity score generation and matching were performed, as previously described, by using the R package MatchIt (R Foundation for Statistical Computing, Vienna, Austria) (5, 14) . Briefly, propensity score estimates representing the probability of intravenous contrast material administration were generated the incidence of AKI in patients who underwent contrast-enhanced or unenhanced CT was examined. In that prior study, the incidence of AKI was examined in an unadjusted cohort of patients stratified according to baseline eGFR. However, propensity score adjustment and subsequent analysis were performed only in patients who were stratified according to baseline SCr level, and not in those who were stratified according to eGFR. In a similar fashion to that in the previous study, patients were included in the current study if they (a) underwent contrast-enhanced or unenhanced abdominal, pelvic, or thoracic CT between January 1, 2000, and December 31, 2010; (b) had sufficient pre-and postscanning SCr data during expected development of AKI (24 hours prior to and 24-72 hours following CT); and (c) had the necessary demographic variables for the Modification of Diet in Renal Disease (MDRD) eGFR equation. Patients were excluded if they (a) had preexisting dialysis requirements prior to or on the day of the scanning or (b) underwent additional contrastenhanced procedures within a 14-day period of the scanning. Patients were also excluded if they had a diagnosis of acute renal failure in the 14 days prior to their scanning, as determined by the date of the acute renal failure ICD-9-CM diagnostic code. Only the most recent scan obtained per patient was examined in patients in whom multiple scans were obtained during the study time frame (13) . Patients were classified into groups of those who underwent contrast-enhanced CT (contrast material group) or those who underwent unenhanced CT (non-contrast material group).
Baseline Renal Function Stratification
Baseline eGFR was calculated for each patient from the SCr results obtained 24 hours prior to CT by using the MDRD equation on the basis of the Kidney Disease Outcomes Quality Initiative (KDOQI) recommendations of the National Kidney Foundation (9,11). At our institution, SCr assays were traceable to isotope dilution mass spectrometry starting in September 2006. Conversely, patient baseline renal function was the most influential covariate for the subgroup with eGFR of 30-59 mL/min/1.73 m 2 . Small differences in the influence of other covariates were also noted among eGFR subgroups.
One-to-one matching on the propensity score yielded a cohort of 12 508 matched patients in whom contrast-enhanced and unenhanced CT scans were obtained (821 patients in the contrast material group and 821 patients in the non-contrast material group for the subgroup with eGFR of 90 mL/min/1.73 m (Table 1) . Propensity score adjustment improved covariate balance in all matched eGFR subgroups. Increasing patient age and incidence of diabetes mellitus, diabetic nephropathy, chronic and acute renal failure, and congestive 
Discussion
This retrospective, single-center study demonstrates that intravenous contrast material administration in doses used for CT scanning is not associated with an increased risk of AKI in a predominantly inpatient cohort. The current study builds on our prior publication in which we applied similar methods to patient populations and in which we defined renal dysfunction and risk thresholds for AKI according to baseline SCr rather than eGFR (5). In both the prior and the current studies, we observed that the incidence of AKI increased in patients with worsening baseline renal function. However, rates of SCr-defined AKI were similar between propensity score-matched groups of patients who received intravenous contrast material and those who did not receive it. The current findings provide additional evidence that the incidence of intravenous contrast material-mediated AKI is obscured by comparable rates of contrast material-independent AKI and suggest that eGFR-based definitions of AKI risk are incapable of aiding identification of true contrast material-mediated AKI from contrast material-independent AKI.
Our finding of similar likelihoods of AKI between contrast material and non-contrast material groups in any eGFR subgroup was not affected by sample size limitations. The smallest subgroups in our analysis were patients at lowest risk (the subgroup with a baseline eGFR  90 mL/ Propensity Score-adjusted Incidence of AKI Following propensity score matching, the incidence of AKI in both the contrast material and the non-contrast material groups significantly increased with diminishing eGFR ( In two recent studies, a metaanalysis of controlled studies (4) and a retrospective study (5), we also demonstrated a similar risk of AKI between patients who received intravenous contrast material and control groups of patients who did not (4, 5) . In our prior propensity score-based study in which we stratified patients according to baseline SCr level into low-risk (SCr level of , 1.5 mg/dL [,132.6 mmol/L]), medium-risk (SCr level of 1.5-2.0 mg/dL [132.6-176.8 mmol/L]), and high-risk (SCr level of  2.0 mg/ dL [176.8 mmol/L]) subgroups, we also found no significant differences in the incidence of AKI between patients who underwent contrast-enhanced and unenhanced CT in any risk subgroup (5). Our current study results expand on the findings in these prior studies by using measurement and stratification of patient baseline renal function according to eGFR, which more accurately reflects actual GFR compared with SCr level (9, 10) . Investigators in few prior studies of contrast materialmediated AKI utilized baseline eGFR as a means of risk stratification (17) (18) (19) (20) (21) (22) , and none of these studies were appropriately controlled with a matched patient cohort not exposed to intravenous contrast material. In our studies, we utilized propensity score matching to balance contrast material and non-contrast material groups with a wide range of clinical characteristics, including age, sex, Charlson comorbidity score, and the presence of comorbidities that can predispose patients to AKI.
However, two large propensity score-adjusted studies by Davenport et al (23, 24) showed apparent escalating incidence of AKI in patients with a baseline SCr level of greater than 1.5 mg/dL (.132.6 mmol/L) and in patients in the group with a baseline eGFR lower than 30 mL/min/1.73 m 2 in whom a contrast-enhanced CT scan was obtained compared with patients in whom an unenhanced scan was obtained. Despite the seemingly similar significant differences in the incidence of AKI as small as 1.1% can be detected (assuming an AKI rate of 1% and an upper CI limit of 2.15). Among highest-risk patients, significant differences in the incidence of AKI as small as 3.5% can be detected (assuming an AKI rate of 14% and an upper CI limit of 1.30). Because the magnitude of these differences is min/1.73 m 2 , n = 1642) and patients at highest risk (the subgroup with a baseline eGFR , 30 mL/min/1.73 m 2 , n = 1486) of developing AKI. The CIs for the ORs of developing AKI can be used to determine the smallest significant difference between contrast material and non-contrast material groups that can be detected with our study. Among lowest-risk patients, , which increased the precision of the resulting ORs.
The incidence rates of AKI in our current study are similar to those in other published studies in which the researchers examined AKI following contrast-enhanced CT. In our previous SCr level-stratified propensity scoreadjusted study (5), we also included unadjusted eGFR-stratified results, as shown in table E1 of that article. In that prior study, unadjusted AKI rates ranged from 2% (613 of 34 149) in the group with an eGFR of higher than 90 mL/min/1.73 m 2 to 12% (1322 of 11 484) in the group with an eGFR of lower than 30 mL/min/1.73 m 2 (5). In the current study, adjusted AKI rates ranged from 1% (21 of 1642) in the group with an eGFR of higher than 90 mL/min/1.73 m 2 to 14% (207 of 1486) in the group with an eGFR of lower than 30 mL/min/1.73 m 2 . These rates of AKI are consistent with results in prior published studies by Thomsen and Morcos (20) and Kim et al (17) who reported an incidence rate of 8% (four of 51) and 12% (seven of 58), respectively, in patients with a baseline eGFR of lower than 30 mL/min/1.73 m 2 . Weisbord et al (22) reported an AKI incidence rate of 10% (five of 51) in patients with a baseline eGFR of 45 mL/min/1.73 m 2 or lower. Our study improves on these prior eGFR studies applied to the entire cohort. Because both study cohorts consisted predominantly of patients with normal renal function and only a small fraction of patients with significant renal insufficiency, a single propensity score model of the entire cohort would be heavily influenced by most of the patients with normal renal function. As such, this approach may not account for the different clinical characteristics of the renal insufficiency patient groups and statistical methods utilized by Davenport et al (23, 24) and those utilized in our current and prior study (5) , several key methodological differences may account for the disparate results. First, our findings were derived from propensity scores generated for each distinct renal function subgroup (defined by eGFR in the current study and SCr level in the prior study) instead of the approach of Davenport et al where a single propensity score model was CONTRAST MEDIA: Risk of Intravenous Contrast Material-mediated Acute Kidney Injury McDonald et al renal function who are most at risk for developing AKI, and in our study, we did not observe evidence of contrast material-mediated AKI in those groups. Sixth, while we used KDOQI chronic kidney disease stage cutoffs to stratify patients according to the eGFR, it is possible that some patients in the more severe risk strata were assigned to the stratum only because of transiently diminished renal function. While the KDOQI stages are relevant to long-term assessment of renal function, this practice is not commonly performed to assess risk prior to contrast material administration. Finally, it is possible that the incidence of contrast material-independent AKI in our cohort was high enough to obscure true contrast material-mediated AKI. Additional studies are necessary to further assess a causal association between contrast material and AKI.
In conclusion, our findings provide additional evidence that the administration of intravenous contrast material does not increase the risk of AKI, even in patients with substantially compromised renal function. and suggests that these confounders probably had a minimal effect on our findings (5).
Our study had several additional limitations. First, our study population consisted predominantly of inpatients; our results are therefore not generalizable to outpatient populations. Second, we specifically excluded patients who received multiple doses of contrast material within a 14-day interval. Our study findings may not extend to these patients. Third, our cohort consisted of a mix of patients who received low-osmolar or isoosmolar contrast material. Because our institutional use of iso-osmolar contrast material is largely limited to patients with a baseline SCr level of greater than 2.0 mg/dL (.176.8 mmol/L) (approximately an eGFR of , 40 mL/min/1.73 m 2 ), we were unable to directly compare a similar patient population to assess contrast material specificity. Fourth, our use of ICD-9-CM codes to identify comorbidities may have been affected by coding errors; however, these errors were probably present in a similar distribution between the contrast material and non-contrast material groups. Fifth, the MDRD equation is known to lead to an underestimation of GFR in patients with normal renal function (eGFR . 60 mL/min/1.73 m 2 ) (25), and such underestimation may lead to improper classification of baseline renal function and potentially aberrant estimates of AKI in these groups. However, the MDRD equation is accurate in patients with compromised by examining a much larger patient population and by matching contrast material recipients with a control group of patients by using propensity score adjustment.
Selection bias remains a concern of all nonrandomized retrospective studies. In an effort to address this limitation, we performed in silico randomization and matching on the basis of a propensity score of the probability of receiving iodinated contrast material. This propensity score incorporated many clinical variables associated with the development of AKI that can affect the decision to administer iodinated contrast material, including baseline SCr level, age, sex, race, relevant comorbidities, and Charlson comorbidity score. This approach minimized selection bias by balancing the relevant common covariates among contrast material and non-contrast material patient groups. Despite these efforts, unmeasured confounders may exist that could have affected our results. In particular, patients who received contrast material may have been more likely to receive intravenous hydration or other prophylactic measures compared with patients who underwent unenhanced CT. Likewise, patients who were administered potentially nephrotoxic medications at the time of scanning may have been less like to receive contrast material. This information, which could not be easily retrieved from the medical record, could have affected our study results. However, our prior counterfactual analysis on this patient cohort represents a fairly robust sensitivity analysis * Numbers in parentheses are percentages, and percentages were rounded. † The odds ratio (OR) refers to the OR of AKI in the contrast material group compared with that in the non-contrast material group. Numbers in parentheses are 95% confidence intervals (CIs). ‡ P values were determined by using the Yates corrected x 2 test.
